Clinical Trials on Repetitive TMS (rTMS) in Italy

Total 23 results

Bayer

Completed

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Relapsing Remitting MS (RRMS) | Secondary Progressive MS (SPMS)

France, Germany, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Czech Republic, Italy, Jordan, Lebanon, Turkey, Israel, Portugal, Netherlands, Iran, Islamic Republic of
University of Padova

Completed

Effects of a Ketogenic Diet on Psychological Outcomes

Overweight | Mood | Appetitive Behavior

Italy
University of L'Aquila

Completed

Efficiency of Neuromuscular Bite vs Physiotherapy in TMD Patients (BENEFIT)

TMD

Italy
Azienda Ospedaliero Universitaria Maggiore della...
Polo AgriFood - Miac Scpa; Albertengo Panettoni

Completed

NUTRACORE, Glycaemic Index and Appetite (NTRCR-vivo)

Hyperglycemia | Hyperinsulinism | Appetitive Behavior | Hyperglycemia, Postprandial | Consumer Preference

Italy
Università degli Studi di Sassari

Completed

Arthrocentesis and Temporomandibular Joint Disorders a Conservative Alternative to Surgical Treatments

TMJ Internal Derangement

Italy
Sidoti & Tartaglia Srl

Completed

Clinical Efficacy of Polynucleotides TMJ Injections Compared to Physiotherapy.

TMJ Pain | TMJ Disease

Italy
University of Pisa

Recruiting

Treatment Outcomes in Patients With Muscular Temporo-mandibular Joint Disorders

TMD | TMD/Orofacial Pain

Italy
S.M. Misericordia Hospital

Completed

Prospective Study to Assess DES Re-endothelization in BMS Restenosis and De-novo Lesions (DESERT)

Stable Coronary Artery Disease | Silent Myocardial Ischemia | In-stent(BMS)Restenosis | De-novo, Atherosclerotic, Coronary Lesions

Italy
Neuromed IRCCS
University of Rome Tor Vergata

Not yet recruiting

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

Healthy | Neuromyelitis Optica | Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
Bayer

Completed

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (BEACON)

Relapsing Remitting Multiple Sclerosis (RRMS)

China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
Fondazione Italiana Sclerosi Multipla
Opera CRO, a TIGERMED Group Company

Unknown

Understanding Evaluation of Patient Information Sheets by User Testing Method

MS (Multiple Sclerosis)

Italy, Romania
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Novartis Pharmaceuticals

Completed

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis (OCTIMS)

Multiple Sclerosis | RRMS

Spain, Czechia, Germany, Australia, Italy, Switzerland, Denmark, United States, United Kingdom, Canada, Netherlands, Poland
Biogen
AbbVie

Terminated

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab (SUSTAIN)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy, United States, Canada, Germany, Puerto Rico
Novartis Pharmaceuticals

Terminated

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (TOFIINGO)

Relapsing Remitting Multiple Sclerosis (RRMS)

Germany, Spain, Australia, Israel, Switzerland, Italy, Austria, Greece, Hungary, Czech Republic, Finland
Novartis Pharmaceuticals

Completed

Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) (TNBC)

Advanced Triple Negative Breast Cancer (TNBC) With High TAMs

France, Italy, Austria, Taiwan, United States, Spain, Australia, Korea, Republic of, Belgium, Germany, Hong Kong, Turkey
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)

United States, Canada, Germany, Italy, Spain, United Kingdom, France
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation

Taiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States, Japan, Taiwan, Spain, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, United Kingdom
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)

Progressive Multiple Sclerosis (PMS)

United States, Canada, Brazil, France, Netherlands, Ireland, Germany, Italy, Poland, Russian Federation, Spain, Colombia, Morocco, Hungary, Denmark, Lebanon, Mexico, Costa Rica, Bosnia and Herzegovina, Czechia, Egypt, Guatemala, Panama and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

Multiple Sclerosis (MS)

United States, Lebanon, Spain, Sweden, Poland, Italy, Estonia, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Korea, Republic of, Lithuania, Norway, Portugal, Romania, Russian Federation and more
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Multiple Sclerosis (MS)

United States, Belgium, Spain, Taiwan, Italy, Germany, Canada, Estonia, Mexico, Croatia, Slovakia, Turkey, India, Argentina, France, Australia, Austria, Serbia, Brazil, Guatemala, Latvia, Poland, Portugal, Russian Federation, Romania, United... and more

Clinical Trials on Repetitive TMS (rTMS) in Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations